NDC 0942-9393 Cpda-1

Anticoagulant Citrate Phosphate Dextrose Adenine

NDC Product Code 0942-9393

NDC 0942-9393-02

Package Description: 70 mL in 1 BAG

NDC Product Information

Cpda-1 with NDC 0942-9393 is a a human prescription drug product labeled by Fenwal, Inc.. The generic name of Cpda-1 is anticoagulant citrate phosphate dextrose adenine. The product's dosage form is solution and is administered via intravenous form.

Labeler Name: Fenwal, Inc.

Dosage Form: Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Cpda-1 Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DEXTROSE MONOHYDRATE 2.23 g/70mL
  • TRISODIUM CITRATE DIHYDRATE 1.84 g/70mL
  • ANHYDROUS CITRIC ACID 209 mg/70mL
  • SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 155 mg/70mL
  • ADENINE 19.3 mg/70mL

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Acidifying Activity - [MoA] (Mechanism of Action)
  • Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
  • Anti-coagulant - [EPC] (Established Pharmacologic Class)
  • Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
  • Calcium Chelating Activity - [MoA] (Mechanism of Action)
  • Acidifying Activity - [MoA] (Mechanism of Action)
  • Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
  • Anti-coagulant - [EPC] (Established Pharmacologic Class)
  • Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
  • Calcium Chelating Activity - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Fenwal, Inc.
Labeler Code: 0942
FDA Application Number: BN770420 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 03-01-2007 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2019 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Cpda-1 Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Instructions For Blood Collection Using Anticoagulant Citrate Phosphate Dextrose Adenine Solution, Usp (Cpda-1) Blood-Pack™ Units

  • Rx only Contains Y-Sampling Site for the collection of unanticoagulated whole blood samples for laboratory testing and the DONORCARE™ Needle Guard.Use aseptic technique.Note: Nominal tubing dimensions of product are 0.118” inner diameter x 0.025” wall thickness.Note: If the Y-Sampling Site is not used, donor samples may be collected using an alternate method following standard procedures.Precautions: •Do not use unless the solution is clear. •Before beginning procedure, obtain one access device for each BLOOD-PACK™ unit with Y-Sampling Site to be processed.1.Identify BLOOD-PACK unit using appropriate donor identification system.2.Adjust donor scale to desired collection weight and position primary container on the donor scale as far as possible below donor arm.3.Clamp donor tubing between needle and Y-Sampling Site with hemostat. This step may be performed prior to step 1 or 2.4.Apply pressure to donor’s arm and disinfect site of venipuncture.5.If blood pressure cuff is used, inflate to approximately 60 mmHg.6.Remove needle cover per instructions below:a)Holding the hub and cover near the tamper-evident seal, twist cover ¼ turn to break seal.b)Remove needle cover, being careful not to drag the cover across the needle point.7.Perform venipuncture, appropriately secure donor needle and/or tubing and release hemostat.8.When good blood flow is established, slide the DONORCARE™ Needle Guard over the needle hub into the engaged position. Leave the front third of the needle hub exposed for access. Stabilize the front of the needle guard to arm with tape. (see Figure 1)Note: In difficult collection conditions (e.g. slow blood flow), leave the needle guard disengaged behind the hub during collection. Engage the needle guard at the end of blood collection.9.Mix blood and anticoagulant in primary container at several intervals during collection and immediately after collection.10.Collect the appropriate volume based on BLOOD-PACK unit used.Note: The volume of anticoagulant is sufficient for the blood collection indicated on BLOOD-PACK unit ± 10%.11.Release the pressure on the donor’s arm as appropriate.Precaution: Do not proceed with the remaining steps until the entire whole blood unit is collected.12.To avoid possible contamination of the whole blood unit, before filling whole blood sample tubes, hermetically seal the donor tubing near the Y-Sampling Site on the side leading to the primary container using a metal clip or appropriate alternate method.Precaution: Complete steps 13 - 21 within approximately 4 minutes after sealing the donor tubing to avoid possible clot formation in the tubing.13.To collect samples, insert the access device by pushing firmly into the Y-Sampling Site until the membrane seal is penetrated (see Figure 2).Note: If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon insertion to avoid barrel detaching from Luer.14.Open the cap on the access device (if applicable).15.Directly align the vacuum sample tube with the internal needle in the access device. Insert vacuum sample tube into device until the stopper is punctured.16.Allow vacuum sample tube to fill with blood then remove from the access device.17.Repeat steps 15 and 16 until the desired number of vacuum sample tubes have been filled.Notes: •If the access device needs to be replaced, use a hemostat to clamp the tubing between the needle and the Y-Sampling Site. Then, grasp base of Sampling Site with one hand and pull the access device out with the other hand. Firmly insert the new access device. Remove hemostat and continue sampling. •If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon removal to avoid barrel detaching from Luer. •The access device can only be replaced one time.Precaution: When replacing the access device, be careful to avoid contact with any blood droplets on the Luer or Sampling Site. Discard used access device appropriately.18.Release remaining pressure on donor’s arm.19.If desired, apply hemostat to donor tubing between needle and Y-Sampling Site.20.Withdrawal of Needle (see Figure 3)Precaution: The needle guard must be held stationary while the needle is withdrawn into it.a)Place folded sterile gauze over puncture site and hold in place with finger tip without exerting pressure.b)Hold sides of needle guard near the front, between the index finger and thumb. Pull the tubing smoothly until the needle is locked into the needle guard.c)Confirm the needle lock by: •Listen for the 2nd “click” as the needle is drawn into the needle guard. •Ensure the tubing cannot be pulled through the needle guard.21.Strip blood from donor tubing into primary container, mix and allow the tubing to refill; repeat once.22.Seal at X marks on donor tubing to provide numbered aliquots of anticoagulated blood for typing or crossmatching.Note: Step 23 may be performed prior to step 21 or 22 if desired.23.Remove and discard the Y-Sampling Site and the DONORCARE Needle Guard into an appropriate biohazardous waste container following established procedures.24.Component Preparation: •If a platelet concentrate is to be prepared, it should be separated from the red blood cells within 8 hours after blood collection. •Fresh frozen plasma should be separated from the red blood cells and placed in the freezer at -18°C or colder within 8 hours after blood collection.25.When processing a multiple BLOOD-PACK unit, centrifuge primary and secondary containers to prepare CPDA-1 red blood cells.26.Place primary container in plasma extractor and express plasma into the appropriate empty TRANSFER-PACK™ container by releasing pressure plate and opening closure in tubing of primary container.27.When desired amount of plasma has been removed, clamp tubing between Y and plasma container.28.Hermetically seal and separate transfer tubing between the Y-connector and primary container. Be careful to avoid fluid splatter.29.For further processing with multiple BLOOD-PACK units, use standard component processing and storage techniques.30.Store suspended CPDA-1 whole blood/red blood cells between 1 and 6°C.31.Infuse CPDA-1 whole blood/red blood cells within 35 days of collection.Store at Controlled Room Temperature.USP Definition of “Controlled Room Temperature”United States Pharmacopeia, General Notices.United States Pharmacopeial Convention, Inc.12601 Twinbrook Parkway, Rockville, MDFenwal, Inc.Lake Zurich, IL 60047 USA1-800-933-692507-19-06-112 REV: A06/2011ManufacturerFenwal, Blood-Pack and Transfer-Pack are trademarks of Fenwal, Inc.DONORCARE is a trademark of ITL Corporation© 2011 Fenwal, Inc. All rights reserved

Package/Label Display Panel

  • Code 4R3626 24 UnitsFenwal™Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ UnitDouble For the Collection and Processing of 500 mL BloodY-Sampling Site, DONORCARE™ Needle Guard, 16 ga. Ultra Thin Wall NeedleRx onlyEach unit consists of a PL 146 Plastic primary container with 70 mL of CPDA-1 solution containing 2.23 g Dextrose (monohydrate) USP, 1.84 g Sodium Citrate (dihydrate) USP, 209 mg Citric Acid (anhydrous) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP and 19.3 mg Adenine USP, pH may have been adjusted with sodium hydroxide; one empty 400 mL PL 146 Plastic TRANSFER-PACK™ container.Sterile, non-pyrogenic fluid path.See instructions for use.Store at Controlled Room Temperature (refer to direction insert). •Open pouch by tearing across at notch. •Direct handling of product surfaces prior to extended storage in the foil pouch, may result in mold growth. •Unused units in open foil pouch may be kept up to 60 days by folding and securing open end of foil pouch to prevent possible loss of moisture, provided:I)Units are not removed from foil pouch, or II)Unused units removed from foil pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once. •Units removed from the foil pouch (that are not returned to the pouch within 12 hours) must be used within 4 days (96 hours). Units out of the foil pouch for longer than 96 hours must be discarded.Fenwal, BLOOD-PACK, and TRANSFER-PACK are trademarks of Fenwal, Inc.DONORCARE is a trademark of ITL Corporation.Fenwal, Inc.Lake Zurich, IL 60047 USAMade in USA07-28-05-551 REV: A

* Please review the disclaimer below.